TaiMed Biologics (4147) — Capital Reinvestment Ratio

Latest as of December 2025: 0.65x

TaiMed Biologics (4147) has a Capital Reinvestment Ratio of 0.65x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$25.95 Million) in capital expenditures (NT$16.75 Million). See debt-free asset ratio of TaiMed Biologics to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.65x

Capex / Operating Cash Flow

Operating Cash Flow

NT$25.95 Million

TWD

Capital Expenditures

NT$16.75 Million

TWD

Data as of

Dec 2025

Most recent filing

TaiMed Biologics Capital Reinvestment Ratio (2025–2025)

This chart tracks TaiMed Biologics's Capital Reinvestment Ratio across 1 annual periods. Check cash flow reinvestment rate of TaiMed Biologics to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for TaiMed Biologics (2025–2025)

Year-by-year Capital Reinvestment Ratio for TaiMed Biologics from 2025 to 2025. For live market cap and broader valuation context, see how much is TaiMed Biologics worth.

Year	Reinvestment Ratio	Operating CF (TWD)	Capital Expenditures	YoY Change
2025	0.12x	NT$191.14 Million	NT$22.77 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow